Business Context and Reporting Period
This Form 8-K is a Current Report filed by Bioaffinity Technologies, Inc. on February 4, 2026. The Company is a Delaware corporation with its principal executive offices in San Antonio, Texas. Its common stock (BIAF) and warrants (BIAFW) trade on the Nasdaq Capital Market. The filing announces the scheduling of the Company's 2026 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance.
Material Changes
There are no material financial changes reported in this filing. The primary event is the rescheduling of a stockholder meeting. The Company previously convened a Special Meeting of Stockholders on December 19, 2025, which was adjourned without conducting business due to a lack of quorum.
Guidance, Outlook, and Management Commentary
- 2026 Annual Meeting: The Board of Directors has established April 30, 2026, as the date for the 2026 Annual Meeting of Stockholders.
- Location: The meeting will be held at the Company's principal executive offices at 3300 Nacogdoches Road, Suite 216, San Antonio, TX 78217.
- Agenda: The Company expects to include proposals from the previously adjourned Special Meeting in the definitive proxy statement for the Annual Meeting.
- Stockholder Proposals: Stockholders seeking to bring business before the meeting or nominate directors must provide written notice by February 14, 2026, in compliance with the Company's Amended and Restated Bylaws.
Important Facts for Investors to Verify
- Confirm the date of the 2026 Annual Meeting is April 30, 2026.
- Verify the deadline for submitting stockholder proposals or director nominations is February 14, 2026.
- Monitor the upcoming definitive proxy statement for details on the proposals carried over from the failed December 2025 Special Meeting.
- Note that the Company is classified as an emerging growth company.